Atossa Genetics (NASDAQ:ATOS) Stock Price Passes Below Two Hundred Day Moving Average – Should You Sell?

Atossa Genetics Inc. (NASDAQ:ATOS)’s stock price passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.82 and traded as low as $0.6350. Atossa Genetics shares last traded at $0.6530, with a volume of 900,864 shares trading hands.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Ascendiant Capital Markets increased their target price on shares of Atossa Genetics from $7.75 to $8.00 and gave the company a “buy” rating in a report on Monday, December 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Atossa Genetics in a report on Wednesday, October 8th. Finally, Zacks Research lowered shares of Atossa Genetics from a “hold” rating to a “strong sell” rating in a research report on Monday, October 13th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Atossa Genetics currently has a consensus rating of “Hold” and a consensus target price of $6.33.

Atossa Genetics Stock Performance

The company has a fifty day simple moving average of $0.74 and a two-hundred day simple moving average of $0.82. The firm has a market capitalization of $83.33 million, a PE ratio of -2.69 and a beta of 1.09.

Atossa Genetics (NASDAQ:ATOS) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). On average, equities analysts anticipate that Atossa Genetics Inc. will post -0.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Atossa Genetics

Several institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. raised its holdings in shares of Atossa Genetics by 1,294.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock valued at $33,000 after buying an additional 35,474 shares during the period. Bank of America Corp DE lifted its position in Atossa Genetics by 55.8% in the third quarter. Bank of America Corp DE now owns 155,169 shares of the company’s stock valued at $135,000 after acquiring an additional 55,568 shares during the last quarter. Squarepoint Ops LLC boosted its holdings in shares of Atossa Genetics by 39.9% in the third quarter. Squarepoint Ops LLC now owns 253,343 shares of the company’s stock valued at $220,000 after acquiring an additional 72,235 shares during the period. GSA Capital Partners LLP boosted its stake in Atossa Genetics by 509.0% during the 3rd quarter. GSA Capital Partners LLP now owns 310,754 shares of the company’s stock worth $269,000 after purchasing an additional 259,725 shares during the period. Finally, Vanguard Group Inc. grew its stake in shares of Atossa Genetics by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock valued at $5,270,000 after purchasing an additional 245,717 shares during the last quarter. 12.74% of the stock is currently owned by institutional investors and hedge funds.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.